Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patientswith persistent CMV viremia
Autore:
Salmon-Ceron, D; Fillet, AM; Aboulker, JP; Gerard, L; Houhou, N; Carriere, I; Ostinelli, J; Vilde, JL; Brun-Vezinet, F; Leport, C;
Indirizzi:
Hop Cochin, Dept Internal Med, F-75014 Paris, France Hop Cochin Paris France F-75014 Dept Internal Med, F-75014 Paris, France Hop La Pitie Salpetriere, Dept Virol, Paris, France Hop La Pitie Salpetriere Paris France triere, Dept Virol, Paris, France Hop Paul Brousse, INSERM, SC 10, Paris, France Hop Paul Brousse Paris France aul Brousse, INSERM, SC 10, Paris, France Hop877chat Claude Bernard, Infect & Trop Dis & Virol Dept, Astra Labs, F-75 Hop Bichat Claude Bernard Paris France 18 & Virol Dept, Astra Labs, F-75
Titolo Testata:
CLINICAL INFECTIOUS DISEASES
fascicolo: 4, volume: 28, anno: 1999,
pagine: 901 - 905
SICI:
1058-4838(199904)28:4<901:EOA1CO>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYMERASE CHAIN-REACTION; AIDS PATIENTS; DNA; LEUKOCYTES; DISEASE; PLASMA; QUANTITATION; GANCICLOVIR; RETINITIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Salmon-Ceron, D Hoprancein, Dept Internal Med, 27 Rue Faubourg St Jacques,F-75014 Paris, F Hop Cochin 27 Rue Faubourg St Jacques Paris France F-75014
Citazione:
D. Salmon-Ceron et al., "Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patientswith persistent CMV viremia", CLIN INF D, 28(4), 1999, pp. 901-905

Abstract

A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg . 12 h]) or no treatment in 42 HIV-infected patients with <100 CD4 cells/mm(3) and persistent asymptomatic CMV viremia. All CMV markers (blood culture, pp65 antigenemia, plasma and leukocyte DNA) either became negative or decreased significantly at day 14 in the foscarnet group. CMV brood culture results at day 14 were positive in 14% of those receiving foscarnet versus 60% of control patients (P = .004). However, after the end of treatment, all markers reappeared or the virus load rapidly increased. The probability of CMV disease at 6 months was 43% in both groups. Patients who had or who achieved a negative blood culture at any time had a reduced risk of CMV disease (RR = 2.64; 95% CI = 1.24-5.62; P = .02). This study suggests that sequential courses of intravenous foscarnet might not be a good strategy for preemptive therapy in this population and that in patients with a positive blood marker, treatment able to induce and maintain negative CMV blood cultures could constitute an effective intervention.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 09:39:10